Article History
Accepted: 9 November 2022
First Online: 8 February 2023
Declarations
:
: N. London receives research funding from Merck Sharp & Dohme, LLC regarding HPV-related sinonasal carcinomas and holds stock in Navigen Pharmaceuticals, none of which are relevant to the present manuscript. All other authors declare no competing interests.